香港联交所最新资料显示，12月4日，九源基因(02566)股东将股票存入华泰香港，存仓市值1.12亿港 元，占比11.92%。 九源基因公布，董事会于2025年12月2日议决，视乎市况，公司拟根据购回授权，自本公告日期起至购 回授权届满止期间，使用最多人民币1亿元于公开市场以自有资金购回最多约1090.97万股H股。 ...

消息面上，九源基因公布，拟使用最多1亿元人民币，于公开市场以自有资金购回最多1090.9678万股H 股。董事会认为，当前的股份成交价格并未充分反映公司的内在价值及业务前景，于现况下进行股份购 回将彰显公司及管理层团队对公司的业务发展前景及增长潜力充满信心，最终会为公司带来裨益并为股 东创造价值。 九源基因(02566)今日再涨近8%，截至发稿，涨5.71%，报8.88港元，成交额144.79万港元。 ...

九源基因(02566)公布，董事会于2025年12月2日议决，视乎市况，公司拟根据购回授权，自本公告日期 起至购回授权届满止期间，使用最多人民币1亿元于公开市场以自有资金购回最多约1090.97万股H股。 每次购回的每股H股的实际购回价比紧随每次购回前五个交易日内H股股份平均收市价溢价不得高于5% 或以上。根据购回授权进行购回的H股股份将可能会被注销、持作库存股份或用于股份激励计划。 公司现时现金流量稳健，整体财务状况稳定，可满足公司业务持续发展的需求。董事会认为，当前的股 份成交价格并未充分反映公司的内在价值及业务前景，于现况下进行股份购回将彰显公司及管理层团队 对公司的业务发展前景及增长潜力充满信心，最终会为公司带来裨益并为股东创造价值。 ...

Core Insights - Tianjin Zhonghe Gene Technology Co., Ltd. has completed a Pre-A+ round financing of several tens of millions of yuan [1] - The financing was jointly invested by Guokec Innovation Investment and Tianjin Port Free Trade Zone Industry Development Fund [1] - Dots Capital acted as the exclusive financial advisor for this financing round [1] Company Development - The funds raised will primarily be used to accelerate the development and commercialization of equipment products [1] - The company aims to enhance its synthetic service capabilities as part of its growth strategy [1]

Core Insights - The latest data from the Hong Kong Stock Exchange indicates that on November 12, shareholders of Jiuyuan Gene (02566) deposited stocks into Huatai Hong Kong, with a market value of HKD 97.89 million, accounting for 11.92% of the total [1] Financial Performance - For the six months ending June 30, 2025, Jiuyuan Gene reported revenue of RMB 639 million, representing a year-on-year decline of 9.05% [1] - The company's gross profit was RMB 525 million, down 2.84% year-on-year [1] - The net profit attributable to shareholders was RMB 90.17 million, reflecting a year-on-year decrease of 14.4% [1] - Earnings per share stood at RMB 0.37 [1]

Core Viewpoint - The establishment of the "Digital Fish Medicine" service station by China Pacific Insurance in Baiyun District aims to enhance the health and productivity of the aquaculture industry through technological support and innovative insurance services [1][4][6]. Group 1: Industry Challenges - Frequent animal diseases in aquaculture have led to significant economic losses and hindered the healthy development of the industry due to a lack of professional knowledge and detection capabilities among farmers [2][3]. - The difficulty in disease prevention and control has increased, prompting a need for innovative solutions in agricultural insurance services for the aquaculture sector [4][5]. Group 2: Service Station Features - The "Digital Fish Medicine" service station integrates local expertise and advanced testing equipment from partner companies to create a comprehensive risk warning platform for aquaculture in Baiyun District [13][15]. - Equipped with advanced tools such as automatic ion detectors and PCR testing devices, the service station provides essential testing services for water quality, parasites, and fish viruses [16][17][18]. Group 3: Professional Support - The service station is staffed by qualified aquatic veterinarians with extensive field experience, offering pre-disaster warnings, damage reduction during disasters, and post-disaster recovery services [21][22][23]. - By providing scientific data for targeted interventions, the service station aims to reduce the misuse of medications, ensuring food safety and helping farmers increase their yields [24][25][26].

Core Insights - Cathy Wood, CEO of Ark Invest, highlighted that the AI sector is currently dominated by four major players: OpenAI, Anthropic, Elon Musk's xAI, and Google's Gemini, with competition intensifying among them [1] - Ark Invest is increasing its focus on AI, cloud computing, and the next-generation internet, particularly targeting Chinese tech stocks [1][2] Fund Activities - **ARK Innovation ETF (ARKK.US)**: - Reduced holdings in Roku by approximately 68,000 shares, valued at over $6.5 million, and continued to decrease exposure to Tempus AI by over 107,000 shares, valued at over $8 million [1] - Sold about 138,000 shares of AMD, valued at approximately $22 million, and reduced Roblox holdings by over 38,000 shares, valued at $5 million [1] - **Increased Holdings**: - Acquired approximately 120,000 shares of Intellia Therapeutics, valued at about $1.96 million, and made its first purchase of Alibaba since 2021, buying around 63,000 shares valued at approximately $11 million [2] - Also invested in Baidu, purchasing about 82,000 shares, valued at approximately $11 million [2] - **ARK Next Generation Internet ETF (ARKW.US)**: - Increased Alibaba holdings by about 42,000 shares, valued at over $8 million, while reducing positions in Shopify and Roblox [2] - **ARK Genomic Revolution ETF (ARKG.US)**: - Continued to increase holdings in Arcturus Therapeutics, purchasing approximately 65,000 shares, with a total increase of about 136,000 shares over two weeks [3] - Also added over 17,000 shares of Intellia Therapeutics [3] - **ARK Fintech Innovation ETF (ARKF.US)**: - Increased Alibaba holdings by about 50,000 shares, valued at over $8 million [3] - **ARK Autonomous Technology & Robotics ETF (ARKQ.US)**: - Purchased over 21,000 shares of Baidu and 106,000 shares of Pony.ai, valued at $2.2 million, while reducing holdings in Kratos Defense by about 71,000 shares and completely selling Oklo, valued at $6 million [3]

Core Insights - The collaboration between Hainan and Hong Kong, referred to as the "dual port" linkage, is expected to create significant economic opportunities and enhance regional development [1][2]. Group 1: Economic Cooperation - Hainan successfully issued 5 billion RMB offshore local government bonds in Hong Kong, and signed 30 cooperation projects across various sectors including industrial investment and healthcare [1]. - In the first seven months of this year, 382 new Hong Kong-funded enterprises were established in Hainan, representing a 7.3% year-on-year increase, while actual use of Hong Kong capital reached 11.872 billion RMB, a 99.3% increase [1]. Group 2: Trade and Investment - The zero-tariff policy in Hainan has led to a rapid increase in imports of production equipment from Hong Kong, enhancing the local manufacturing capabilities [2]. - Hainan's government aims to expand bilateral investment and trade, deepen cooperation in retail and consumption, and strengthen exchanges in the exhibition industry and talent mobility [2]. Group 3: Future Opportunities - The full closure of Hainan's free trade port on December 18 is anticipated to provide more development opportunities for the Hainan-Hong Kong collaboration [2]. - The expansion of zero-tariff product categories is expected to facilitate the entry of more high-quality Hong Kong products into Hainan, while also attracting Hong Kong electronic and pharmaceutical companies to establish manufacturing in Hainan [3].

Core Insights - Gene technology is driving a new industrial revolution, transitioning from research to clinical applications and expanding into consumer-level home testing [1][3] - China is leveraging its vast market advantages to drive technological innovation and application in precision medicine and health management, aiming to seize the future of the bio-economy [1][6] - The rapid development of the gene testing industry is reshaping future industry trajectories, with a focus on faster, lower-cost, and more precise testing [3][4] Industry Development - The gene technology sector has entered a fast development phase, with gene testing becoming a core component due to its significant foundational role and practical applications [3][4] - The market price for whole genome sequencing has dramatically decreased from over $30 billion and 13 years for the first human genome to between $1,000 and $10,000 today [4][5] - The potential market size for whole genome sequencing in China alone is estimated to reach trillions of yuan [5] Social Impact - Recent initiatives in Hebei province have successfully implemented non-invasive prenatal genetic testing and free screening for hereditary deafness, significantly controlling severe birth defects [5] - The economic benefits of these health initiatives have been substantial, with a cost-effectiveness ratio of 1:16.73 and 1:15.06 for the respective screening programs [5] Safety and Security - Gene technology plays a crucial role in national security across multiple dimensions, including population, biology, food, ecology, economy, technology, data, and culture [5][6] - High-throughput sequencing technology has been instrumental in identifying new pathogens like SARS and COVID-19, supporting biological safety warning systems [5] International Influence - Domestic sequencing instruments have been deployed across six continents, providing essential support and services to hospitals, universities, and public health institutions globally [5][6] - Chinese scientists are actively involved in planning and constructing biobanks in various countries, contributing to the establishment of a global health community [5][6] Strategic Initiatives - The industry is encouraged to adopt a "Gene+" action plan to integrate gene technology deeply into various economic and social sectors, fostering a cycle of innovation and application [6][8] - There is a call for the establishment of national or regional biobank resources to support gene technology research and enhance sample management and sharing [6][8] - Investment in the entire gene industry chain, including gene testing, synthesis, and therapy, is essential for strengthening domestic capabilities [6][8]

Core Viewpoint - The company announced the progress of litigation related to the transfer of equity in Hainan Hongrun Tianyuan Gene Biotechnology Co., Ltd, indicating that the lawsuit will not adversely affect its current or future profits [1][3]. Group 1: Basic Situation of the Lawsuit - Wuhan Baitai Gene Engineering Co., Ltd and Shanghai Ruian Gene Technology Co., Ltd filed lawsuits against Beijing Hongrun Tianyuan Gene Biotechnology Co., Ltd and Guangxi Wanhou Trading Co., Ltd, claiming that the equity transfer affected their creditor rights [1]. - The Beijing Haidian District People's Court made a first-instance judgment to revoke the equity transfer of 100% of Hainan Hongrun's shares from Beijing Hongrun to Guangxi Wanhou [1]. Group 2: Progress of the Lawsuit - Both parties involved in the lawsuits appealed to the Beijing First Intermediate People's Court after being dissatisfied with the first-instance judgment [2]. - A settlement was reached among the parties during the appeal process, and the plaintiffs applied to withdraw their lawsuits during the second-instance hearing [2]. - The court issued a final ruling to revoke the first-instance judgment and allowed the plaintiffs to withdraw their lawsuits [3]. Group 3: Impact on Company Profits - The settlement and the court's decision to allow the withdrawal of lawsuits indicate that there will be no negative impact on the company's current or future profits [3]. Group 4: Other Litigation Matters - The company and its controlling entities currently have no other significant litigation or arbitration matters that need to be disclosed [3].